
AdvisorShares Psychedelics ETF (PSIL) Price & Chart
PSIL ETF Chart & Stats
- Day’s Range
- $20.80 - $21.26
- 52-Week Range
- $15.63 - $27.02
- Previous Close
- $21.02
- Volume
- 9,154
- Average Volume (3M)
- 33.10K
- AUM
- 45.22M
- NAV
- 20.96
- Expense Ratio
- 1.00%
- Holdings Count
- 30
- Beta
- 0.93
- Inception Date
- Sep 15, 2021
- Last Dividend Ex-Date
- Dec 22, 2025
- Dividend Yield
- (8.98%)
- Shares Outstanding
- 2,154,976
- Standard Deviation
- N/A
ETF Overview
AdvisorShares Psychedelics ETF
The AdvisorShares Psychedelics ETF (ticker: PSIL) offers investors a unique opportunity to delve into the cutting-edge world of psychedelics within the health care sector. As a specialized fund, PSIL focuses predominantly on the burgeoning pharma, biotech, and life sciences niche, where groundbreaking research and innovation are transforming the landscape of mental health and therapeutic treatments. This ETF seeks to capitalize on the growing interest and investment in psychedelic substances, which are increasingly being recognized for their potential to address mental health disorders such as depression, anxiety, PTSD, and addiction. By investing in PSIL, stakeholders gain exposure to a carefully curated portfolio of companies at the forefront of psychedelic drug development and research, positioning themselves at the intersection of health care innovation and market opportunity. Ideal for those looking to diversify their portfolio with avant-garde health care solutions, PSIL stands as a testament to the evolving acceptance and integration of psychedelics into mainstream medicine.
AdvisorShares Psychedelics ETF (PSIL) Fund Flow Chart
PSIL ETF News
PSIL ETF FAQ
What was PSIL’s price range in the past 12 months?
What is the AUM of PSIL?
Is PSIL overvalued?
Does PSIL pay dividends?
How many shares outstanding does PSIL have?
PSIL ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| DFTXDefinium Therapeutics, Inc. | 11.95% |
| CMPSCompass Pathways Plc | 11.53% |
| CYBNTSE:CYBN | 8.36% |
| LLYEli Lilly And Company | 5.66% |
| ABBVAbbvie | 5.34% |
| NBIXNeurocrine Biosciences | 5.05% |
| JNJJohnson & Johnson | 4.76% |
| SPTXSeaport Therapeutics, Inc. | 4.60% |
| RLMDRelmada Therapeutics Inc | 4.53% |
| DRUGBright Minds Biosciences Inc. | 4.45% |
| Total | 66.24% |


